lestaurtinib has been researched along with vx-970 in 1 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (vx-970) | Trials (vx-970) | Recent Studies (post-2010) (vx-970) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 56 | 3 | 56 |
| Protein | Taxonomy | lestaurtinib (IC50) | vx-970 (IC50) |
|---|---|---|---|
| Putative alpha-1-antitrypsin-related protein | Homo sapiens (human) | 0.0002 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3 | |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | 0.0155 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for lestaurtinib and vx-970
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |